|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
ES2133271T3
(es)
|
1989-07-06 |
1999-09-16 |
Univ California |
Receptores para factores de crecimiento de fibroblastos.
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
|
US5863888A
(en)
|
1990-07-06 |
1999-01-26 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Human Bek Fibroblast growth factor receptor
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
DK0590058T3
(da)
|
1991-06-14 |
2004-03-29 |
Genentech Inc |
Humaniseret heregulin-antistof
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
AU3494397A
(en)
|
1996-06-18 |
1998-01-07 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
Fibroblast growth factor receptor activating gene i and related compositions and methods
|
|
ATE296315T1
(de)
|
1997-06-24 |
2005-06-15 |
Genentech Inc |
Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
AU759779B2
(en)
|
1997-10-31 |
2003-05-01 |
Genentech Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
AU760562B2
(en)
|
1997-12-05 |
2003-05-15 |
Scripps Research Institute, The |
Humanization of murine antibody
|
|
PT1071700E
(pt)
|
1998-04-20 |
2010-04-23 |
Glycart Biotechnology Ag |
Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP2278003B2
(en)
|
1999-04-09 |
2020-08-05 |
Kyowa Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
CN1308347C
(zh)
|
1999-04-28 |
2007-04-04 |
德克萨斯大学董事会 |
用于通过选择性抑制vegf来治疗癌症的组合物和方法
|
|
AU7950400A
(en)
|
1999-10-19 |
2001-04-30 |
Kyowa Hakko Kogyo Co. Ltd. |
Process for producing polypeptide
|
|
JP2001302699A
(ja)
|
2000-04-17 |
2001-10-31 |
Nichirei Corp |
ヒトｋｇｆｒに対する抗体
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
EA013563B1
(ru)
|
2000-10-06 |
2010-06-30 |
Киова Хакко Кирин Ко., Лтд. |
Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
|
|
AU2002314495A1
(en)
|
2001-06-20 |
2003-01-02 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
HUP0700103A3
(en)
|
2001-08-03 |
2012-09-28 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
JP2005532253A
(ja)
|
2001-10-25 |
2005-10-27 |
ジェネンテック・インコーポレーテッド |
糖タンパク質組成物
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
CN100531796C
(zh)
|
2002-01-31 |
2009-08-26 |
马普科技促进协会 |
Fgfr激动剂
|
|
CA2492671C
(en)
|
2002-03-22 |
2012-04-17 |
Aprogen, Inc. |
Humanized antibody and process for preparing same
|
|
JPWO2003084569A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物含有医薬
|
|
EP1498490A4
(en)
|
2002-04-09 |
2006-11-29 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PRODUCING ANTIBODY COMPOSITION
|
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
|
AU2003236019A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
|
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
|
KR20050000380A
(ko)
|
2002-04-09 |
2005-01-03 |
교와 핫꼬 고교 가부시끼가이샤 |
게놈이 개변된 세포
|
|
KR100493460B1
(ko)
|
2002-08-29 |
2005-06-07 |
재단법인서울대학교산학협력재단 |
암 세포에서 발현되는 ｆｇｆｒ2 이성체
|
|
EP1944320A1
(en)
|
2002-12-16 |
2008-07-16 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
JPWO2005035586A1
(ja)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
融合蛋白質組成物
|
|
JPWO2005035778A1
(ja)
|
2003-10-09 |
2006-12-21 |
協和醗酵工業株式会社 |
α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
|
|
US20070274981A1
(en)
|
2003-10-16 |
2007-11-29 |
Imclone Systems Incorporation |
Fibroblast Growth Factor Receptor-1 Inhibitors and Methods of Treatment Thereof
|
|
NZ547279A
(en)
|
2003-10-22 |
2008-04-30 |
Keck Graduate Inst |
Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
|
|
ME01775B
(me)
|
2003-11-05 |
2011-02-28 |
Glycart Biotechnology Ag |
Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
|
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
|
EP1697420A2
(en)
|
2003-12-19 |
2006-09-06 |
Five Prime Therapeutics, Inc. |
Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
|
|
WO2005097832A2
(en)
|
2004-03-31 |
2005-10-20 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
|
WO2005115363A2
(en)
|
2004-05-25 |
2005-12-08 |
Yale University |
Method for treating skeletal disorders resulting from fgfr malfunction
|
|
WO2006076288A2
(en)
|
2005-01-11 |
2006-07-20 |
Five Prime Therapeutics, Inc. |
Dna constructs for long-term expression of intravascularly injected naked dna
|
|
US7923538B2
(en)
|
2005-07-22 |
2011-04-12 |
Kyowa Hakko Kirin Co., Ltd |
Recombinant antibody composition
|
|
EP2041575A2
(en)
|
2006-03-31 |
2009-04-01 |
Ordway Research Institute |
Prognostic and diagnostic method for cancer therapy
|
|
WO2007134210A2
(en)
|
2006-05-12 |
2007-11-22 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of cancer
|
|
WO2007146847A2
(en)
|
2006-06-09 |
2007-12-21 |
University Of Maryland, Baltimore |
Glycosylation engineered antibody therapy
|
|
US8101721B2
(en)
|
2006-06-15 |
2012-01-24 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
|
HRP20160082T1
(hr)
|
2006-09-29 |
2016-02-26 |
Oncomed Pharmaceuticals, Inc. |
Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
|
|
US8394927B2
(en)
|
2006-11-03 |
2013-03-12 |
U3 Pharma Gmbh |
FGFR4 antibodies
|
|
CL2007003411A1
(es)
|
2006-11-28 |
2008-07-04 |
Centelion |
Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
|
|
TW200833711A
(en)
|
2006-12-22 |
2008-08-16 |
Genentech Inc |
Antibodies to insulin-like growth factor receptor
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
WO2008090959A1
(ja)
|
2007-01-24 |
2008-07-31 |
Kyowa Hakko Kirin Co., Ltd. |
エフェクター活性が増強された遺伝子組換え抗体組成物
|
|
CA2680046A1
(en)
|
2007-03-23 |
2008-10-02 |
The Translational Genomics Research Institute |
Methods of diagnosing, classifying and treating endometrial cancer and precancer
|
|
CA2682382A1
(en)
|
2007-03-28 |
2008-10-09 |
Biogen Idec Inc. |
Non-fucosylated antibodies
|
|
US20110091473A1
(en)
|
2007-10-22 |
2011-04-21 |
Genmab A/S |
Novel antibody therapies
|
|
US9260525B2
(en)
|
2008-02-04 |
2016-02-16 |
Xiao-Jia Chang |
Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
|
|
US20110059091A1
(en)
|
2008-02-04 |
2011-03-10 |
Xiao-Jia Chang |
Inhibitors of oncogenic isoforms and uses thereof
|
|
WO2009151448A1
(en)
|
2008-06-10 |
2009-12-17 |
University Of Southern California |
Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients
|
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
|
LT2842573T
(lt)
|
2008-11-07 |
2017-12-11 |
Galaxy Biotech, Llc |
Monokloniniai antikūnai prieš fibroblastų augimo faktoriaus receptorių-2
|
|
WO2011025814A1
(en)
|
2009-08-25 |
2011-03-03 |
National Jewish Health |
Methods and compositions for treatment of lung injury
|
|
JP2013508292A
(ja)
|
2009-10-14 |
2013-03-07 |
カロバイオス ファーマシューティカルズ インコーポレイティッド |
ＥｐｈＡ３に対する抗体
|
|
US20120328599A1
(en)
|
2010-01-14 |
2012-12-27 |
Yale University |
Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
|
|
WO2011115937A1
(en)
|
2010-03-14 |
2011-09-22 |
The Translational Genomics Research Institute |
Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
|
|
AU2011253101A1
(en)
|
2010-05-11 |
2013-01-10 |
Aveo Pharmaceuticals, Inc. |
Anti-FGFR2 antibodies
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
CN103201287B
(zh)
|
2010-08-12 |
2016-04-13 |
艾托生物有限公司 |
成纤维细胞生长因子受体2的致癌异构体的抗体分子及其用途
|
|
US20120258496A1
(en)
|
2010-09-27 |
2012-10-11 |
Boehringer Ingelheim International Gmbh |
Production of low fucose antibodies in h4-ii-e rat cells
|
|
EP3219731A1
(en)
|
2010-10-01 |
2017-09-20 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
|
WO2012162561A2
(en)
*
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
|
JP2015505850A
(ja)
|
2011-12-14 |
2015-02-26 |
シアトル ジェネティックス， インコーポレイテッド |
新規な抗体薬物コンジュゲート（ａｄｃ）およびそれらの使用
|
|
US20150329621A1
(en)
|
2012-03-30 |
2015-11-19 |
The Regents Of The University Of California |
Anti-emp2 therapy reduces cancer stem cells
|
|
KR102115143B1
(ko)
|
2012-04-09 |
2020-05-28 |
다이이찌 산쿄 가부시키가이샤 |
항 ｆｇｆｒ２ 항체
|
|
US9254288B2
(en)
|
2012-05-07 |
2016-02-09 |
The Translational Genomics Research Institute |
Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
|
|
WO2013173223A1
(en)
|
2012-05-15 |
2013-11-21 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
US20150191791A1
(en)
|
2012-07-05 |
2015-07-09 |
Lsip, Llc |
Fgfr2 fusion gene
|
|
WO2014089193A1
(en)
|
2012-12-04 |
2014-06-12 |
Aveo Pharmaceuticals, Inc. |
Anti-fgfr2 antibodies
|
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
US9415118B2
(en)
|
2013-03-13 |
2016-08-16 |
Novartis Ag |
Antibody drug conjugates
|
|
AU2014259956A1
(en)
|
2013-05-01 |
2015-11-12 |
Five Prime Therapeutics, Inc. |
Methods of treating cancer
|
|
CN105658810B
(zh)
|
2013-06-13 |
2020-08-21 |
南澳大学 |
用于检测前列腺癌的方法
|
|
PH12021552742A1
(en)
|
2013-08-01 |
2022-05-23 |
Five Prime Therapeutics Inc |
Afucosylated anti-fgfr2iiib antibodies
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
US20170175197A1
(en)
|
2014-01-29 |
2017-06-22 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
|
CA2961439A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
CN116327924A
(zh)
|
2015-11-23 |
2023-06-27 |
戊瑞治疗有限公司 |
用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
|
|
PT3624837T
(pt)
|
2017-05-16 |
2025-10-01 |
Five Prime Therapeutics Inc |
Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro
|